Sugi Predict

Sugi Predict / Compounds / SCHEMBL910232

SCHEMBL910232

SCHEMBL910232

O=C(O)CCC(NC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 6/20 0.70
▸ MME P08473 1/20 0.64
▸ ECE1 P42892 1/20 0.64
▸ NAALAD2 Q9Y3Q0 1/20 0.61
▸ PPARA Q07869 2/20 0.57
▸ PPARG P37231 1/20 0.57
▸ SIRT2 Q8IXJ6 1/20 0.56
▸ SIRT1 Q96EB6 1/20 0.56
▸ CASP1 P29466 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL28226069 1.00 FOLH1 (0.70) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL910233 1.00 FOLH1 (0.70) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL910423 1.00 FOLH1 (0.70) FOLH1MMEECE1NAALAD2PPARA
Cyclopropane SCHEMBL5691187 0.96 FOLH1 (0.65) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL24238520 0.95 FOLH1 (0.64) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL9697060 0.95 FOLH1 (0.64) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL19925534 0.95 FOLH1 (0.64) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL9698236 0.95 FOLH1 (0.64) FOLH1MMEECE1NAALAD2PPARA
SCHEMBL9697579 0.95 MME (0.65) FOLH1MMEECE1NAALAD2CASP1
SCHEMBL19307785 0.95 FOLH1 (0.64) FOLH1MMEECE1NAALAD2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108290919-B Azithromycin derivatives having epithelial barrier enhancing properties 艾比恩多制药有限责任公司 2022-06-17 — — CN claimed
CN-104151398-A Method for synthesizing dipeptide with glutamic acid as first amino acid residue SICHUAN TONGSHENG AMINO ACID CO LTD 2014-11-19 — — CN claimed
CN-101969920-B Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same SHISEIDO CO LTD 2013-09-18 — — CN claimed
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same SHISEIDO COMPANY LTD. (JP) 2011-01-06 — — US claimed
EP-2255780-A1 PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME Shiseido Company, Ltd. (JP) 2010-12-01 — — EP claimed
US-6395077-B1 INKS WITH BENZOYLBENZOIC ACID AND COLORS XEROX CORPORATION 2002-05-28 — — US claimed
US-5990266-A Degradable polyesters, a mixed culture of microorganisms for degrading these polyesters, and methods for making these substances UNIVERSITY OF NEBRASKA (US) 1999-11-23 — — US claimed
WO-1999028366-A1 DEGRADABLE POLYESTERS BOARD OF REGENTS OF UNIVERSITY OF NEBRASKA (US) 1999-06-10 — — WO claimed
US-3978035-A POLYPEPTIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DT) 1976-08-31 — — US claimed
JP-57093942-A — — None — — JP disclosed
WO-2026041802-A1 AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF INFECTIONS EPIENDO PHARMACEUTICALS EHF (IS) 2026-02-26 — — WO disclosed
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12252504-B2 Oligosaccharide-protein conjugates GENZYME CORPORATION (US) 2025-03-18 — — US disclosed
US-20240382611-A1 PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES MERSANA THERAPEUTICS, INC. 2024-11-21 — — US disclosed
JP-S5793942-A NOVEL INOSITOL DERIVATIVE, ITS ALUMINUM SALT, PEPTIC ULCER REMEDY COMPRISING IT, AND ITS PREPARATION NIPPON CHEMIPHAR CO LTD 1982-06-11 — — JP disclosed
EP-0027319-A2 Method for reductive elimination of protecting groups and preparative process using such method AJINOMOTO CO., INC. (JP) 1981-04-22 — — EP disclosed
US-4218479-A Novel benzylalcohols and pharmaceutical compositions and use thereof TANABE SEIYAKU CO., LTD. (JP) 1980-08-19 — — US disclosed
US-4131686-A ANTIDIABETIC TANABE SEIYAKU CO., LTD. (JP) 1978-12-26 — — US disclosed
US-3952021-A α-(3,4-Dimethoxyphenethylaminomethyl)-3,4 or 3,5-dihydroxybenzylalcohols and salts thereof TANABE SEIYAKU CO., LTD. (JA) 1976-04-20 — — US disclosed
US-3932429-A Novel azabicyclo octane derivative and process for preparing same TANABE SEIYAKU CO., LTD (JA) 1976-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS FOLH1 4439/4885MME 2449/4885ECE1 2832/4885
US-20240382611-A1 PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES CD2BP2, DNPEP, LNPEP FOLH1 30/4885MME 221/4885ECE1 2182/4885
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same CUTA, GLRA3, ARGLU1 FOLH1 4099/4885MME 4339/4885ECE1 2247/4885
US-12252504-B2 Oligosaccharide-protein conjugates MAN2B1, GAA, GBA1 FOLH1 641/4885MME 991/4885ECE1 3152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.